Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus purchased 138,700 shares of the firm’s stock in a transaction on Friday, May 25th. The shares were acquired at an average cost of $9.62 per share, for a total transaction of $1,334,294.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Public Equities L.P. Invus also recently made the following trade(s):

  • On Wednesday, May 30th, Public Equities L.P. Invus purchased 433,378 shares of Lexicon Pharmaceuticals stock. The shares were acquired at an average cost of $9.94 per share, for a total transaction of $4,307,777.32.

Lexicon Pharmaceuticals opened at $11.60 on Friday, Marketbeat Ratings reports. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -9.13 and a beta of 0.42. Lexicon Pharmaceuticals, Inc. has a one year low of $7.67 and a one year high of $18.00. The company has a current ratio of 2.72, a quick ratio of 2.70 and a debt-to-equity ratio of 8.85.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 140.09% and a negative return on equity of 213.32%. The company had revenue of $25.21 million for the quarter, compared to the consensus estimate of $25.30 million. During the same period in the previous year, the firm earned ($0.33) earnings per share. The firm’s revenue for the quarter was up 37.8% on a year-over-year basis. analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -1.33 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. LPL Financial LLC increased its stake in shares of Lexicon Pharmaceuticals by 34.1% in the first quarter. LPL Financial LLC now owns 29,172 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 7,426 shares during the period. A.R.T. Advisors LLC increased its stake in shares of Lexicon Pharmaceuticals by 71.0% in the first quarter. A.R.T. Advisors LLC now owns 54,266 shares of the biopharmaceutical company’s stock worth $465,000 after buying an additional 22,533 shares during the period. UBS Group AG increased its stake in shares of Lexicon Pharmaceuticals by 94.5% in the first quarter. UBS Group AG now owns 218,923 shares of the biopharmaceutical company’s stock worth $1,876,000 after buying an additional 106,392 shares during the period. Stifel Financial Corp increased its stake in shares of Lexicon Pharmaceuticals by 15.9% in the first quarter. Stifel Financial Corp now owns 104,656 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 14,378 shares during the period. Finally, Cim Investment Mangement Inc. increased its stake in shares of Lexicon Pharmaceuticals by 171.4% in the first quarter. Cim Investment Mangement Inc. now owns 42,709 shares of the biopharmaceutical company’s stock worth $366,000 after buying an additional 26,973 shares during the period.

Several research analysts have commented on the stock. Wedbush reissued an “outperform” rating and set a $40.00 price target (down from $42.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, May 22nd. BidaskClub raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 17th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 8th. Citigroup decreased their price target on shares of Lexicon Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday, May 4th. Finally, Stifel Nicolaus decreased their price target on shares of Lexicon Pharmaceuticals from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, May 4th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $24.40.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.